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’ INTRODUCTION
Transport of retinol [ROH (Figure 1)] in the blood is
controlled by the lipocalin serum retinol binding protein
(sRBP, 21 kDa), which is synthesized and released from the
liver as a complex with a second protein, transthyretin (TTR).13
sRBP consists of an N-terminal coil, eight antiparallel β-strands
(AH) forming a barrel, and a short R-helix close to the
C-terminus [Protein Data Bank (PDB) entry 1RBP4].1 ROH is
accommodated in the barrel with the β-ionone ring positioned
innermost, the polyene chain fully extended, and the hydroxyl
end group nearly solvent-exposed near the AB, CD, and EF
loops (Figure 1). Circulating in the plasma, sRBP is bound to
TTR, a homotetramer of∼56 kDa. Each TTRmonomer consists
of eight antiparallel β-strands (AH) arranged like a Greek key
β-barrel. One tetramer of TTR can bind two sRBP molecules in
vitro;5 however, because of a significantly higher concentration of
TTR compared to that of sRBP, each tetramer forms a 1:1
complex in plasma.6 This association of the sRBPROH com-
plex with TTR is believed to prevent its filtration through the
kidney glomeruli.3 In the blood, the uncomplexed or free form of
sRBP interacts with a receptor in the plasma membrane of
virtually all cells in a ROH-sensitive manner.7,8 Only the TTR-
dissociated holo-sRBP is able to bind to the receptor with high
affinity, because of steric hindrance of access to the sRBPsRBP
receptor binding site.710 Binding of sRBP to its receptor is
followed by the release of retinol and its uptake into the cell via
the sRBP receptor.
A notable paper11 has chronicled the evidence of the involve-
ment of sRBP in obesity, insulin resistance, and type 2 diabetes.
The level of sRBP is elevated in insulin resistant mice and
humans with obesity and type 2 diabetes.12 sRBP is mostly
secreted by the liver but can also come from other tissues,
including adipocytes.13 The source of this excess sRBP is thought
to be visceral adipose tissue, hence the link to obesity. sRBP
acting on peripheral tissues such as skeletal muscle is postulated
to attenuate insulin sensitivity, as indicated by reduced IRS1
phosphorylation and PI3K activity.11 The mechanism of this
proposed effect is unknown but should involve a sRBP-binding
entity of some kind.
Fenretinide [4-hydroxy(phenyl)retinamide (FEN) (Figure 1)]
is a synthetic retinoid and has been investigated for potential use
in the treatment of cancer, cystic fibrosis, rheumatoid arthritis,
acne, psoriasis, and Stargardt’s disease.14,15 Previously, FEN has
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been shown to compete with retinoids for binding to sRBP (PDB
entry 1FEL),16 disrupting sRBPTTR complexes and resulting
in urinary secretion of sRBP and systemic depletion of ROH.17
Administration of FEN has been observed to exert therapeutic
Figure 1. (A) Three-dimensional image of ROH (blue) in sRBP (PDB entry 1RBP4) and FEN (yellow) in sRBP (PDB entry 1FEL16) with contacting
residues labeled and illustrated in stick format. Images are shown with a 6 rotation around the y axis. Images produced using Pymol.39 (B and C) Two-
dimensional (2D) depiction of ROH and FEN binding poses as depicted using MOE.20 (D) Legend for the 2D interactions in the binding pose as
depicted using MOE.
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effects in mouse models of obesity and diabetes.15 Long-term
FEN treatment prevents high-fat diet-induced obesity, insulin
resistance, and hepatic steatosis.18
The hypothesis we are exploring is that agents that reduce sRBP
levels or disrupt the protein interactions that sRBP undergoes will
prevent the genesis of insulin resistance and consequently that of type
2 diabetes. In this work, we developed a series of retinoid analogues
that were first evaluated experimentally for binding to sRBP through
fluorescence measurements. Subsequently, their ability to disrupt
proteinprotein interactionswas examined throughpull-down, time-
resolved fluorescence resonance energy transfer (TR-FRET) and
surface plasmon resonance (SPR) assays of sRBPTTR complexes
and SPR assays of sRBP with solubilized membranes containing the
sRBP receptor. The latter is a novel focus in an effort to identify
compounds that exhibit a dual or different effect. Compounds that
exhibit differences in their ability to inhibit sRBPTTR and
sRBPsRBP receptor interactions may provide an approach to
examining both the validity and the mechanism of action of sRBP
levels in the context of insulin resistance and type 2 diabetes.
’RESULTS
Retinoid Analogues.We were largely interested in establish-
ing if the retinoids could bind to sRBP without necessarily
penetrating deep into the binding pocket. We also wished to
investigate the level of variability allowed at the region of the
molecule near the entrance to the binding cavity, thought to be
the effective moiety with regard to alterations in conformation.
We were also interested in determining if steric hindrance was
the sole and main mechanism for inhibition or whether a
conformational change was also required.
Traditional medicinal chemistry around both ends of a known
chemical scaffold (ROH/FEN) was utilized to develop a novel
series of retinoid analogues (Figure 2). The target compounds
168 were prepared as outlined in Schemes 13 (see Experi-
mental Section), and all chemical structures are shown in the
Supporting Information.
The approach of the analysis of these compounds was
structured on three levels. The first binding to sRBP was
monitored using quenching of the fluorescence of the intrinsic
tryptophan in sRBP and/or inhibition of the FRET response of
bound retinol. The second involved the sRBPTTR interaction
as monitored by pull-down and SPR responses. The third
monitored sRBPsRBP receptor interactions in solubilized
membrane preparations using SPR. Only compounds that pro-
vided some evidence of binding to sRBP progressed to the
second and third stages.
Binding of Compounds to sRBP. To study the interaction
between retinoid analogues and sRBP, the quenching of the
intrinsic tryptophan (Trp) fluorescence of the apoprotein fol-
lowing excitation at 280 nm was measured in the presence of
increasing concentrations of the compounds. ROH binds to the
ligand binding site of the sRBP and produces a quenching of the
Trp fluorescence. Those compounds that absorbed in the
emission region of Trp reduced this emission in a dose-depen-
dent manner, indicative of their specific interaction with apo-
sRBP (Figure 3). The fluorescence intensities of the compounds
in an N-acetyltryptophanamide solution were measured to
correct the titration curves. The change in fluorescence intensity
was used to calculate the apparent dissociation constants (Kd) for
the proteincompound interactions as described by Cogan
et al.19 The Kd values for selected compounds are listed in
Table 1. A Kd of 182( 4 nM was obtained for the ROHsRBP
complex, in agreement with that reported in the literature for the
protein isolated from human plasma.19 The other compounds
had an affinity in the same range (Table 1).
Effect of Compounds on the sRBPTTR Interaction De-
termined by a Pull-Down Assay. The ability of the 68 library
compounds to disrupt the interaction between sRBP and its
partner, TTR, was first examined using a pull-down assay. The
purified ROHsRBPTTR complex, as indicated in Experi-
mental Section, was utilized. Both proteins were incubated
together in the presence of ROH and the various compounds,
at 10 and 100 μM, respectively. The difference in concentration
between ROH and the compounds allowed for the detection of
their inhibitory effect. After incubation with the different com-
pounds, the flow-throughs were run in SDS gels and the free
sRBP disrupted from the complexes was detected by silver
staining. A representative result for ROH and FEN is shown in
Figure 4A. FEN, which is known to disrupt the interaction
between sRBP and TTR, was used as a control to which potential
positive compounds could be compared. A small quantity of free
sRBP was always obtained in the negative control flow-through
(no compound added), as a consequence of the relatively weak
interaction (Kd ≈ 0.3 μM) between the two proteins.21 FEN
produced an estimated 35-fold increase in the amount of sRBP
released from the complex. The shorter retinoid analogues,
222, which did not exhibit absorption in the Trp emission
region, also did not show the ability to disrupt the sRBPTTR
interaction and were disregarded in further studies. A number of
compounds based on scaffold B (1 and 2368) showed a similar
disruptive effect on the complex with FEN. The dose-dependent
effect of the positive compounds was similarly assessed using
increasing concentrations of the analogues, as shown for one
selected compound, 58 (Figure 4B).
Figure 2. 2D image of Fenretinide (FEN), which differs fromROHby a
phenylamide in place of the hydroxyl group. (A) Area where the varia-
tions were introduced at the β-ionone ring end of FEN (compounds
222). (B) Polyene end of FEN where variations were introduced
(compounds 1 and 2368).
Scheme 1
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sRBPTTR Interaction Assessed by TR-FRET. To estimate
the potency of the different inhibitors selected in the pull-down
assay, we continued our analysis of the compounds using a TR-
FRET assay based on a methodology developed previously.22
The sRBP used in this assay was a recombinant protein expressed
with a His tag in Pichia pastoris,23 to which an europium anti-
His antibody was bound. Native TTR was labeled with biotin.
When both proteins bind, and after excitation of europium with
light at 340 nm, energy is transferred from europium to strepta-
vidin-conjugated allophycocyanin (APC) and the emission of
light can be detected at 665 nm. A stronger signal is observed as
the affinity between both proteins increases with ROH concen-
tration. The TR-FRET signal was measured against increasing
concentrations of ROH and a constant concentration of inhi-
bitor. The system was tested first with FEN from 0.1 to 50 μM,
and from this experiment, an appropriate concentration of
10 μM was selected to study the inhibitory effect of the com-
pounds. A set of ROH doseresponse curves in the presence of
inhibitory compounds is shown in Figure 5. The compounds
demonstrated a competitive antagonist effect, as previously
shown for FEN,22 with a shift of the ROH response curve to
the right. FEN produced a 30-fold increase in the EC50 (Table 2).
Additionally, compounds 1 and 58 had a strong effect, with a
15-fold increase, while the rest of the compounds tested in the
TR-FRET assay produced an only slight increase in the EC50
(23-fold).
sRBPTTR Interaction Assessed by Surface Plasmon Re-
sonance.We sought to further expand our understanding of the
best retinoid analogues by studying their ability to disrupt the
interaction between sRBP and TTR in real time using a surface
plasmon resonance (SPR) assay. As shown in Figure 6, the only
compound that strengthens the interaction between sRBP and
TTR is ROH, as expected. None of the analogues strengthened
the interaction with TTR, but all of them, with the exception of
compound 1, were less disruptive than FEN itself and hence
exhibited qualitatively the same results that were seen in the
TR-FRET analysis.
sRBPReceptor Interaction Assessed by Surface Plasmon
Resonance. The ability of the compounds to disrupt the
interaction between sRBP and solubilized membranes was also
examined using the SPR binding assay. Detergent-treated
HEK293 membrane fractions were preincubated with com-
pounds and then injected over sRBP immobilized on the sensor
chip surface. All the novel retinoid compounds tested had a
negative effect on the stability of the sRBPmembrane protein
complex and consequently produced faster dissociation (Figure 7).
However, FEN had little or no effect. All experiments were
repeated at least three times with no significant differences. Note
that background binding to other components of the solubilized
membrane will be present.
’DISCUSSION
For some time, there has been great concern about the link
among obesity, insulin resistance, type 2 diabetes, and cardio-
vascular disease. A recent scientific discovery provided a way
forward toward preventing the avalanche of disability due to type
2 diabetes. This was the observation that elevated sRBP levels
may attenuate the response of the cell to insulin, thus increasing
resistance and presaging type 2 diabetes.11 A second important
element was the much earlier demonstration and functional
characterization of a plasma membrane receptor for sRBP24,25
through which the effects of sRBP might be mediated. The
connection with insulin action is a novel one, suggesting cross
talk between RBP and insulin, because higher levels of the former
are seen to inhibit the intracellular response to insulin.13
There has been some controversy about whether sRBP
levels are statistically correlated with the development parti-
cularly of type 2 diabetes, with reports both confirming2629
and failing to confirm3032 the link. The reasons for these
differences are not clear, the only suggestion put forward so far
being some variation in the methodologies used for sRBP
estimation,29 but very significantly, the first studies on isolated
human adipocytes confirmed that an elevated sRBP level
Scheme 2
Scheme 3
Figure 3. Titration of apo-sRBP with a selection of compounds. For
quenching of the protein fluorescence, the excitation and emission
wavelengths were 280 and 345 nm, respectively. The titration system
consisted of 0.5 mL of 2 μM purified apo-sRBP in PBS (pH 7.4).
Solutions of ROH, FEN, or compounds in ethanol were added to the
cuvette until a final concentration of 7.5 μM was reached. The curves
were corrected for the inner filter effect of the compounds.
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does indeed attenuate insulin-induced IRS-1 and ERKI/2
phosphorylation.13 Moreover, as found in the whole-animal
studies, the serine residue on IRS-1 specifically affected was that
closely identified with insulin signaling. Considering all this, it
seems possible that reducing the “activity” of elevated levels of
sRBP may restore normal insulin sensitivity and counteract type
2 diabetes.
The hypothesis we are exploiting is that compounds that
reduce sRBP levels or disrupt its protein interactions will prevent
the genesis of insulin resistance and consequently that of type 2
diabetes and its cardiovascular complications. Administration of
FEN has been observed to exert therapeutic effects in mouse
models of obesity and diabetes.15,18 Long-term FEN treatment
prevents high-fat diet-induced obesity, insulin resistance, and
hepatic steatosis.18 Additionally, retinoic acid (RA) treatment
was determined to reduce body weight and basal serum glucose,
serum ROH, and sRBP levels coupled with improved insulin
sensitivity and to decrease the ROH:sRBP ratio.33 In this work, a
series of retinoid analogues were synthesized and examined for
their ability to disrupt the interaction of sRBP with TTR and, for
the first time, with its receptor. As a first step, we assessed the
binding of these compounds to sRBP by fluorescence titration, a
well-established method.19 The fluorescence emission data were
used to calculate Kd values according to the method of Cogan
et al.19 The values obtained were consistent with previous
work,19,34 with a Kd for ROH binding to sRBP of 182 ( 4 nM
and comparable values for analogues 1 and 2368. This is in
agreement with earlier findings, which indicated that modifica-
tions of the functional hydroxyl end group of ROH (see Figure 2
and schemes in Experimental Section) do not change substan-
tially the affinity for apo-sRBP.17,19,35 Compounds 222 did not
show any absorption in the Trp emission region, and their
binding to sRBP could not be assessed by this method. It has
been shown that, to interact specifically with sRBP, retinoids
must possess an intact trimethylcyclohexenyl group that estab-
lishes close contacts with the side chains of the internal β-barrel
cavity.35 The lack of a cyclohexene ring or having a shorter
structure may limit the binding affinity of compounds 222 for
sRBP, indicating that the strength of the interaction lies in the
polyene chain region.
In the available crystal structures, the ROH hydroxyl group is
near the protein surface, in the region of the entrance loops
surrounding the opening of the binding cavity. It participates in
polar interactions and becomes fully buried in the holo-sRBP
TTR complex.4 However, the cyclohexene ring and the isoprene
tail of FEN take the place of the corresponding portions of ROH,
while the hydroxyphenyl amide group protrudes from the cavity
toward the solvent, replacing the ROH hydroxyl group and a
water molecule hydrogen bonded to it.16
Subsequent analysis focused on compounds 1 and 2368
with an examination of their effect on the interaction between
sRBP and TTR. For this purpose, we developed a pull-down
Table 1. Apparent Dissociation Constantsa (Kd) for the ProteinCompound Interactions Calculated According to theMethod of
Cogan et al.19
aData shown are average values ( the standard deviation (SD) from three independent experiments.
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assay that could detect free sRBP released from the ROHsRBP
TTR complex after its disruption in the presence of compounds.
The crystal structure of holo-sRBP complexed with TTR re-
vealed that ROH participates in the interaction of sRBP with
TTR,4 increasing the affinity of the sRBPTTR interaction
Figure 6. Sensorgram showing interactions of His-sRBP with TTR in
the presence of selected compounds. SPR response curves reflect the
interaction of TTR with immobilized sRBP. The responses were
recorded as a function of time and are expressed in resonance units (RU).
Figure 7. Sensorgram showing interactions of His-sRBP with solubi-
lized HEK293 cell membranes in the presence of selected compounds.
SPR response curves reflect the interaction of HEK293 cell solubilized
membrane preparations passed over immobilized sRBP. The responses
were recorded as a function of time and are expressed in resonance units
(RU).
Figure 5. Time-resolved FRET for the sRBPTTR interaction. Assays
were conducted with a fixed concentration (10 μM) of compound and
increasing concentrations of ROH. sRBP and TTR concentrations were
5 and 100 nM, respectively. TR-FRET signals are the ratios between 665
and 615 nm emissions. The curves were generated using a sigmoidal
doseresponse equation in Prism (GraphPad Software Inc.). Results
shown are from a representative experiment performed in duplicate (
the standard deviation.
Figure 4. Pull-down assay for sRBP after incubation with compounds.
(A) The ROHsRBPHis-TTR complex was incubated in the pre-
sence of 10 μMROHand 100 μMFEN. After incubation, the complexes
and free sRBP were separated by a pull-down assay and the flow-throughs
analyzed by SDSPAGE. Lanes reveal free sRBP in the flow-through
fractions: lane 1, control (10 μM ROH, no compound); lane 2, 10 μM
retinol and 100 μM FEN (positive control for complex disruption). (B)
Doseresponse pull-down assay for 58. Lane 1 was the control (10 μM
ROH, no compound). Lanes 26 contained 10 μM ROH and different
concentrations of 58 (1, 10, 20, 50, and 100 μM, respectively).
Table 2. EC50 Values for ROHsRBPTTR Interaction in
the Presence of Compoundsa
compound EC50 (nM)
no compound 71( 11
Fenretinide 2372( 186
1 1260( 177
23 245( 35
41 171( 21
48 145( 5
58 954( 114
62 154( 17
aData shown are average values ( the standard deviation from three
independent experiments.
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6-fold, from 1.2 to 0.3 μM.21 This relatively low affinity, even for
the holoprotein, is physiologically significant: because holo-sRBP
complexed with TTR lacks affinity for its membrane receptor,9,10
a small amount of uncomplexed holo-sRBP is needed to deliver
ROH to the cells through this specific receptor. On the other
hand, FEN, with a structure similar to that of ROH but contain-
ing a bulky phenylamide in place of the hydroxyl group,
drastically interferes with the sRBPTTR interaction because
of steric hindrance in the contact regions between sRBP and
TTR and also changes in the position of the loops surrounding
the entrance of the binding site. In agreement with these
observations, a small amount of free sRBP was always detected
in the control without compounds after incubation of the holo-
sRBPTTR complex in the pull-down assay. In comparison, a
larger amount of free sRBP (estimated to be 35-fold) could be
measured after incubation of the complex with FEN. Com-
pounds 222 did not show the ability to disrupt the sRBPTTR
interaction and will be disregarded in further studies. However,
a number of compounds based on scaffold B [with variations in
the outer end (1 and 2368)] showed a similar disruptive effect
on the complex with FEN and probably act through the same
mechanism. Interestingly, some of the larger groups at the
polyene end of the retinoid analogues extend farther than FEN
but do not disrupt the sRBPTTR interaction, indicating
that the retinoid analogues may not function solely as steric
blockers but perhaps induce conformational changes in the
loop regions. This shall be further examined in the crystal
structure work.
We cannot calculate accurate Ki values because of the nature
of the pull-down assay. In all runs (tested at least three times) of
this assay, the band intensities were very similar to those for FEN,
indicating a disruptive effect with a potency similar to that of
FEN. From this qualitative analysis, we could draw no definitive
conclusions regarding the strength of the disruption of the best
analogues, and hence, additional studies were pursued to validate
our initial findings. We used a TR-FRET assay, a technique that
has been recently applied to the study of sRBPTTR interac-
tions, to characterize their inhibitory behavior.22 The selected
compounds produced a decrease in the strength of the basal
interaction between sRBP and TTR in the absence of ROH and
a right shift of the ROH curve compared to the control (no
compound). This is in agreement with the competitive behavior
described for FEN and retinyl acetate.22 The TR-FRET results
were also validated using a secondary binding assay, SPR, which
yielded qualitatively similar results, with FEN and compound 1
exhibiting a more disruptive sRBPTTR interaction effect,
while the other compounds were clustered together in both
assays.
With the SPR assay using the HEK293 cell membranes and
immobilized His-sRBP, ROH had a positive effect on the
interaction observed in real time and the compounds all had a
disruptive effect, with FEN exhibiting the smallest disruption
of the set. We have given values for the disruption of the
RBPTTR interaction from FRET assays, but it is not possible
to generate other than relative potencies for the sRBPreceptor
interactions because of the nature of SPR with solubilized whole
membrane preparations. The usual problem is that accurate
values can be obtained only when pure preparations of a receptor
are used.
Using our three-tiered assay approach, including analyzing
binding to sRBP and SPR studies of the sRBPTTR and
sRBPsRBP receptor interaction, we were able to show that
most sRBP binders exhibited a dual effect. Some compounds
inhibited TTR more than the receptor interaction and a few the
reverse. It is known that FEN reduces sRBP levels and improves
insulin sensitivity,11,16,36 probably by disrupting the ROHsRBP
TTR complex promoting clearance of sRBP.11,17 Our SPR data
suggest that FEN might have a dual effect on the RBP insulin
resistance link: (i) lowering sRBP levels and (ii) interacting directly
with the insulin pathway inside the cell, its uptake having been
mediated by the sRBP receptor. This is supported by the observa-
tion that FEN only “mildly” interferes with the interaction of the
sRBPROH complex with the membrane compared to the strong
disruption of that interaction caused by other compounds.
’CONCLUSIONS
In this work, a number of active retinoid-like molecules
that inhibit sRBPTTR and sRBPreceptor interactions as
well as or better than FEN, the antitumor positive control, have
been identified, thereby presenting a potential novel dual mecha-
nism of action. Thus, the compounds discovered may offer a
new therapeutic intervention against type 2 diabetes and its
development.
’EXPERIMENTAL SECTION
Biology. Materials. Escherichia coli strain BL21(DE3), P. pastoris
strain KM71H (aox1::ARG4, arg4), expression vector pPICZR A, the
Zero Blunt TOPO PCR cloning kit, and europium-labeled anti-His tag
antibodies were purchased from Invitrogen. HEK293 cells (human
embryonic kidney) were from the ATCC. SureLight streptavidin-con-
jugated allophycocyanin (APC) was from PerkinElmer. The EZ-Link
Sulfo-NHS-LC-Biotinylation kit was from Pierce. ROH, FEN, native
human TTR, and synthetic oligonucleotide primers were from Sigma.
Polymerase chain reaction (PCR) amplification of coding sequences was
performed with PfuTurbo Hotstart DNA polymerase from Stratagene.
Ni-NTA superflow resin and cobalt affinity gel were purchased from
Qiagen and Sigma, respectively. Plasmid isolation and gel extraction kits
were fromQiagen. Biacore materials were obtained fromGEHealthcare.
Retinoid analogues were synthesized by Sygnature Chemical Services.
Other reagents used were molecular biology grade.
Expression and Purification of Recombinant Human sRBP in E. coli.
The mature form of human sRBP was expressed without tags using
vector pMMHa. NdeI and BamHI restriction sites flanking the coding
sequence of mature human sRBP (corresponding to residues 19201)
were constructed by PCR using the sRBP cDNA originally cloned into
the pQE-30 vector.9 The oligonucleotide primers designated to amplify
the insert were NdeI (forward) 50-TACATATGGAGCGCGACTGCC-
GAGTG-30 and BamHI (reverse) 50-TAGGATCCCTACAAAAGGT-
TTCTTTCTGATCTGC-30. The PCR product was inserted into the
pCR-Blunt II TOPO vector, digested with NdeI and BamHI, and
introduced into the same restriction sites of the pMMHa vector under
the control of the T7 promoter.
BL21(DE3) cells transformed with expression plasmid pMMHa-
sRBP were grown in 2YT medium (1.6% tryptone, 1% yeast extract,
and 0.5% NaCl) with 100 μg/mL ampicillin. When the cell culture
reached an optical density of 0.6 at 600 nm, protein expression was
induced with 1 mM IPTG. After overnight incubation at 37 C, the cells
were harvested by centrifugation at 7000g for 10 min at 4 C and
subjected to disruption by sonication. The resulting suspension was
centrifuged at 10000g for 10 min at 4 C and the pellet (sRBP inclusion
bodies) suspended at a concentration of 1 mg/mL sRBP in 5 M
guanidinium chloride with 10 mM DTT at pH 9.0 to help in the
reduction and solubilization of recombinant protein. After overnight
incubation at 25 C, the refolding of sRBP was started by dilution of the
4385 dx.doi.org/10.1021/jm200256g |J. Med. Chem. 2011, 54, 4378–4387
Journal of Medicinal Chemistry ARTICLE
denatured protein to a concentration of 0.25 mg/mL in cold refolding
buffer [25 mM Tris-HCl (pH 9.0), 0.3 mM cystine, 3 mM cysteine, and
1 mM EDTA] with a 10-fold molar excess of ROH.37 The guanidinium
chloride concentration at this step was 1 M. After refolding, the protein
solution was dialyzed against PBS buffer, and then refolded sRBP was
purified by affinity chromatography with His-TTR (see below).
Expression and Purification of Recombinant Human sRBP in
P. pastoris. The sRBP was expressed with an N-terminal His tag using
theP. pastoris expression systemas described previously.23The sRBP coding
sequence was amplified by PCR using the oligonucleotide primers EcoRI
(forward) 50-GAATTCCATCATCATCATCATCATGAGCGCGACT-
GCCGAGTG-30 and XbaI (reverse) 50-TCTAGACTACAAAAGGTTT-
CTTTCTGATCTGCC-30. The forward primer included the sequence for
a six-His tag. The PCR product was ligated in the pCR-Blunt II TOPO
vector and subsequently introduced into the EcoRI and XbaI sites of the
pPICZR A vector under the control of the AOX1 promoter.
P. pastoris cells were transformed with expression vector pPICZR
A-His-sRBP and grown at 30 C in phosphate-buffered YPmedium [1%
yeast extract and 2% peptone (pH 7.5)] in the presence of 2% glycerol
(w/v) until the OD600 reached 6.0. The cells were harvested by
centrifugation at 7000g for 10 min and used to inoculate YP medium
to an OD600 of 1.0 supplemented with 1% methanol (v/v) to induce
expression. For each of 2 days, methanol was added to a final
concentration of 1% (v/v). After induction for 48 h, the culture
supernatant containing the His-sRBP was incubated with Ni-NTA resin
and the bound proteins eluted with elution buffer [20 mM Na2HPO4,
500 mM NaCl, and 250 mM imidazole (pH 7.4)]. The purified His-
sRBP was dialyzed against PBS buffer and then concentrated by
ultrafiltration.
Expression and Purification of Recombinant Human His-TTR. The
coding sequence of human TTR in vector pMMHa was a gift from J. W.
Kelly.38 To facilitate the subsequent purification of the holo-sRBP
TTR complex, we expressed TTR with an N-terminal His tag. The
coding sequence of mature TTR (corresponding to residues 21147)
was inserted into the BamHI and HindIII restriction sites in the pQE-30
vector. The oligonucleotide primers used in the PCR were BamHI
(forward) 50-GGATTCGGCCCTACGGGCACCG-30 and HindIII
(reverse) 50-AAGCTTTCATTCCTTGGGATTGGTGACG-30. The
PCR product was ligated in the pCR-Blunt II TOPO vector, digested
with BamHI and HindIII, and inserted into the pQE-30 vector.
The expression of this protein in E. coli was performed as for sRBP.
After overnight induction with IPTG, the cells were collected and
sonicated. The supernatant containing the soluble TTR was incubated
with Ni-NTA resin and the recombinant protein eluted with elution
buffer. The purified His-TTR was dialyzed against PBS buffer.
Purification of the ROHsRBPTTR Complex. PurifiedHis-TTRwas
added to the refolded, untagged holo-sRBP solution and the mixture
incubated overnight at 4 C in the presence of 100 μMROH. Then, the
protein solution was applied to a cobalt affinity column equilibrated with
buffer I [20 mM Na2HPO4, 500 mM NaCl, and 10 mM imidazole (pH
7.4)]. The columnwas washed with the same buffer and then eluted with
elution buffer. Fractions were analyzed by SDSPAGE and Coomassie
staining.
Fluorimetric Binding Assays. The binding of compounds to His-
sRBP was monitored by titration of the intrinsic fluorescence emission
of the protein in the presence of increasing concentrations of com-
pounds. The quenching of protein fluorescence due to the transfer of
energy to the ligand was evaluated using excitation and emission
wavelengths of 280 and 350 nm, respectively, in a Cary Eclipse
fluorescence spectrophotometer (Varian). Purified His-sRBP expressed
with the P. pastoris system was diluted to a concentration of 2 μM in PBS
buffer, and small increments of compound solutions in ethanol were
added. The systemwasmixed and allowed to equilibrate for 5min before
the fluorescence emission of the compoundHis-sRBP complex was
recorded. The final concentration of ethanol never exceeded 2%. A
solution of N-acetyl-L-tryptophanamide was used as a blank. The
apparent dissociation constants (Kd) of compounds from His-sRBP
were estimated as described by Cogan et al.19
sRBPTTR Interaction Assessed by Pull-Down Assay.The capacity of
the compounds that bind to sRBP to disrupt the interaction between this
protein and its partner TTR was examined first by a pull-down assay. In
this assay, the purified holo-sRBPTTR complex [0.2 mg/mL in PBS
buffer (pH 7.4)] was incubated in the presence of 10 μM retinol and
each compound at 100 μM, for 1 h at 37 C. Then, 20 μL of cobalt resin
was added to separate by pull-down assay the fraction of free sRBP from
the fraction bound to TTR. The flow-throughs, containing the free
sRBP, were examined by SDSPAGE and silver staining. A control with
FEN, which is known to disrupt the interaction between sRBP and TTR,
was included in the assay for comparison.
Time-Resolved FRET. The TR-FRET assay was based on the pre-
viously published protocol of Coward et al.22 The reactionmixtures were
prepared in white 96-well plates (Greiner) in a final volume of 100 μL.
Native TTR was biotinylated according to the manufacturer's manual.
Each well contained 5 nM apo-His-sRBP, 100 nM biotinylated TTR,
100 nM SureLight streptavidin-conjugated APC, 1 nM europium-
labeled anti-His tag antibody, 10 μM inhibitor, and increasing concen-
trations of ROH in TR-FRET buffer [20 mM Tris-HCl (pH 7.4),
150 mM NaCl, 1 mM EDTA, 0.01% BSA, and 0.02% Tween 20].
Reaction mixtures were incubated for 2 h at room temperature and
measured on a POLARstar Omega microplate reader (excitation wave-
length of 337 nm, emission wavelengths of 615 and 665 nm).
Surface Plasmon Resonance (SPR). Interaction analyses were per-
formed in SPR running buffer (HBS with 50 μMEDTA) at a flow rate of
10 μL/min, at a constant temperature (25 C), using a Biacore 3000
system (GE Healthcare). Ni-NTA sensor chips were used for all
experiments, and general procedures were performed according to the
manufacturer’s instructions for this sensor chip. Briefly, each cycle
consisted of surface activation with 20 μL of nickel (2 min), followed
by a 5min injection of recombinant sRBP (His-tagged, 200 nM solution,
prepared in SPR running buffer), followed by a 1 min pulse of a specific
concentration of compound (diluted in SPR running buffer), culminat-
ing with (i) a 5 min injection of untagged, native TTR (1 μM in running
buffer incubated with each compound at 10 μM) or (ii) a 5min injection
of solubilized HEK293 cells membranes9 (50 μg/mL in running buffer
incubated with each compound at 10 μM). Finally, sensor chip
regeneration was achieved by stripping all proteins from the surface,
performing a 2 min injection of 0.3 mM EDTA in HBS, at the end of
each cycle (maximal number of regenerations per chip, 100). Sensor
chips were used for 2 weeks, or until the level of nonspecific binding
increased (g5%). All experiments were performed in parallel with an
inactivated flow cell not coated with protein. Each independent experi-
ment was repeated three to five times.
Data Processing. Prism 5.00 (GraphPad Software Inc.) was used to
determine EC50 values. All SPR sensorgrams were corrected for buffer-
induced refractive index changes at an uncoated reference surface,
analyzed using BIAEVALUATION version 3.2 (GE Healthcare).
Chemistry. For the determination of compound purity, the system
consisted of a Waters HPLC and mass spectrometer system and an
Agilent Scalar 5 μm C18 50 mm  4.6 mm column. Detection was
achieved using an electrospray ionization source (positive or negative
ion) and a UV detector at 254 and 215 nm. Mobile phase A was 0.1%
aqueous formic acid, andmobile phase Bwas 0.1% formic acid inMeCN.
The flow rate was 2.5 mL/min. The following gradient was used: 5% B
from 0 to 0.1min, 5 to 95%B from 0.1 to 5min, 95%B from 5 to 5.5min,
95% B from 5.5 to 5.6 min, flow rate increased to 3.5 mL/min, 95% B
from 5.6 to 6.6 min, 95 to 5% B from 6.6 to 6.75 min, 5% B from 6.75 to
6.9 min, 5% B from 6.9 to 7 min, flow rate reduced to 2.5 mL/min. The
majority of the library supplied was >95% pure.
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Preparation. Retinoic acid (1 g, 3.33 mmol) and EDCI (0.957 g, 4.99
mmol) were stirred in DCM (20mL), andmethyl 2-(4-aminophenoxy)-
acetate (0.724 g, 3.99 mmol) was added (Scheme 1). After 16 h, the
reaction mixture was applied to a silica cartridge (80 g) and eluted with
an EtOAc/isohexane mixture (1:3, v/v) to afford the target compound
as a yellow oil that solidifies on standing.
1, methyl 2-{4-[(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclo-
hex-1-en-1-yl)nona-2,4,6,8-tetraenamido]phenoxy}acetate: tR = 3.02
min; m/z 464 (M þ H)þ (ESþ); yield 0.5226 g, 34%; 100% pure.
Preparation. 4-Hydroxyaniline (43.6 mg, 0.399 mmol) was added to
a solution of cis-retinoic acid (100 mg, 0.333 mmol) and EDCI (96 mg,
0.499 mmol) in DCM (1mL) (Scheme 2), and the reaction mixture was
stirred at room temperature overnight.
The reaction mixture was diluted with water and passed through a
phase separator. The organic layer was applied to a 4 g silica cartridge
and eluted with 0 to 100% EtOAc in cyclohexane. This gave a yellow
solid.
23, (2Z,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-tri-
methylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide: tR = 2.82 min;
m/z 392 (M þ H)þ (ESþ); yield 13.6 mg, 10%; 94% pure.
Preparation. Amine (0.4 mmol, 1.2 equiv) was added to retinoic acid
(100mg, 0.333 mmol) and EDCI (96mg, 0.499mmol) in DCM (1mL)
(Scheme 3). The reaction mixtures were then stirred at room tempera-
ture for 24 h. All reactions were investigated by LCMS. Those showing
the desired product were quenched with water, and the mixture was
passed through a phase separator. Products were purified by preparative
HPLC.
41, (2E,4E,6E,8E)-N-(2,3-dihydroxypropyl)-3,7-dimethyl-9-(2,6,6-
trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide: tR = 4.72 min;
m/z 374 (M þ H)þ (ESþ); yield 7.8 mg, 6%; 92% pure.
48, (2E,4E,6E,8E)-N-(2-hydroxyethyl)-3,7-dimethyl-9-(2,6,6-trimethyl-
cyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide: tR = 2.60 min; m/z 344
(M þ H)þ (ESþ); yield 12.2 mg, 11%; 90% pure.
Amine (0.4 mmol, 1.2 equiv) was added to Retinoic acid (100 mg,
0.333 mmol), and EDCI (96 mg, 0.499 mmol) in DCM (1 mL). The
reaction mixtures were then stirred at room temperature for 24 h. All
reactions were investigated by LCMS. Those showing the desired
product were quenched with water, and the mixture was passed through
a phase separator.
All products were purified on 4 g silica cartridges eluting with a 0 to
100% gradient (5% MeOH in EtOAc) in isohexane.
58, (2E,4E,6E,8E)-N-[4-(dimethylamino)phenyl]-3,7-dimethyl-
9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamide: tR =
3.22 min; m/z 419 (M þ H)þ (ESþ); yield 15.3 mg, 11%; 91% pure.
62, (2E,4E,6E,8E)-3,7-dimethyl-1-morpholino-9-(2,6,6-trimethylcy-
clohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-one: tR = 3.09 min; m/z 370
(M þ H)þ (ESþ); yield 10.8 mg, 9%; 98% pure.
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